The biotech buyout bonanza

A building owned by pharmaceutical company Sanofi
Sanofi has acquired two drug companies so far in 2018. Stephane de Sakutin / AFP via Getty Images

Pharmaceutical giants are once again acquiring smaller biotechnology companies after a lull in activity — deals that become a lot easier for drug companies to stomach after the Republican tax overhaul allowed them to repatriate overseas cash.